Gene expression analysis in two cohorts of EGFRM+ NSCLC patients treated with gefitinib or osimertinib showed frequent concomitant overexpression of AXL and CUB domain-containing protein-1 (CDCP1) in cases with poor response to these drugs [265]. This evidence concerns the gene CDCP1 and non-small cell lung carcinoma.